Carl Zeiss Meditec AG : Carl Zeiss Meditec improves its results in first six months of financial year 2012/2013

Tuesday, 14. May 2013 07:00

Carl Zeiss Meditec AG / Carl Zeiss Meditec AG : Carl Zeiss Meditec improves its results in first six months of financial year 2012/2013 . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.

Revenue grows to € 443 million; positive trend for intraocular lenses and in microsurgery

In the first six months of financial year 2012/2013 medical technology company Carl Zeiss Meditec increased its revenue by 2.6% compared with the same period of the previous year, to € 443 million. Earnings before interest and tax improved to € 64.1 million (previous year: € 61.1 million); the EBIT margin rose to 14.5% (previous year: 14.1 percent).

JENA, 14 May 2013
Fuelled by persistently dynamic growth in the intraocular lens business and a continued positive trend in Microsurgery, the Company further increased its revenue and earnings. As reported in the ad hoc disclosure in April, the first-quarter revenue deficit in the Ophthalmic Systems business was reduced, although this took longer than was anticipated at the end of the first quarter.
"Our widespread presence in various business fields and regions enables us to even out any fluctuations in business and to continue our long-term growth trend," says Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG. "We are therefore sticking firmly to our innovation strategy, the expansion of our business in the growth markets and to our overriding objectives." 

Revenue by business unit 

Once again, the largest revenue contribution in the first half of the year came from the Microsurgery strategic business unit (SBU). Bolstered by a continued rise in demand for visualization systems for microsurgery, this SBU achieved revenue growth of 6% to € 206.7 million (previous year: € 195.1 million).
The Ophthalmic Systems SBU was affected by a high level of competition. The effects of the model change in the area of optical coherence tomography (OCT) also impacted this SBU. A 4.9% decline in revenue to € 175.8 million was countered in the first six months of the year by a positive trend in incoming orders, which slightly surpasses the previous year's level.
The development of business in the Surgical Ophthalmology SBU was very positive in the first six months of the year. The double-digit revenue growth (+16.4%) to € 60.5 million, compared with € 51.9 million in the same period of the previous year, is mainly due to very good sales figures in the premium segment for intraocular lenses for minimally invasive cataract surgery. The picture in terms of reporting regions was once again quite mixed in the first six months of the year. Although there were positive impulses from both China and Japan and Latin America, as well as very good contributions to growth from Germany and Russia, business was characterized by consumer reticence in the USA and a decline in Southern Europe.  Overall, this resulted in growth of 2.1% in the EMEA region, a largely stagnating development in the Americas (-0.1%) and a continuation of robust growth, even after the inclusion of significant currency effects, of 5.9% in the Asia/Pacific region.

 Outlook - well equipped for further growth

With consistent expansion of our solutions business, based on a broad product range and a balanced regional distribution of business, the Company is sticking firmly to its goals to increase the share of case-number-dependent products and services to 25% by 2015 and to achieve a total EBIT margin of 15%. Steady growth is expected for the current financial year. "We anticipate revenue of between € 880 and 910 million," says Ludwin Monz.

Revenue by strategic business unit

Figures in € '000 6 Months 2011/2012 6 Months 2012/2013 Change from previous year
Ophthalmic Systems 184,781 175,766 -4.9%
Surgical Ophthalmology 51,942 60,459 16.4%
Microsurgery 195,075 206,732 6.0%

Revenue by region

Figures in € '000 6 Months 2011/2012 6 Months 2012/2013 Change from previous year
EMEA 149,423 152,625 2.1%
Americas 144,083 143,875 -0.1%
Asia / Pacific region 138,292 146,457 5.9%

Press contacts:

Jann Gerrit Ohlendorf, Corporate Communications, Carl Zeiss Meditec AG
Phone+49 3641 220-331, E-Mail:

Contact for investors:
Henriette Meyer, Investor Relations, Carl Zeiss Meditec AG
Phone +49 3641 220-106, E-Mail:

Carl Zeiss Meditec AG
Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. It provides complete packages of solutions for the diagnosis and treatment of eye diseases, including implants and consumable materials. The company creates innovative visualization solutions in the field of microsurgery. The medical technology portfolio of Carl Zeiss Meditec is rounded off by promising, future-oriented technologies such as intraoperative radiotherapy. In financial year 2011/2012 (ended 30 September) the Group's more than 2,400 employees generated revenue of almost € 862 million. The head office of Carl Zeiss Meditec is in Jena, Germany.
The company has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Research and Development (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 35 percent of Carl Zeiss Meditec shares are in free float. The remaining approx. 65 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries.
Fore more than 160 years Carl Zeiss has been contributing to the progress of technology on the markets for Industrial Solutions, Research Solutions, Medical Technology and Consumer Optics, improving the quality of life for many people. Carl Zeiss AG, Oberkochen, is wholly owned by the Carl Zeiss Foundation.

For more information visit our website at:

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Carl Zeiss Meditec AG via Thomson Reuters ONE


--- End of Message ---

Carl Zeiss Meditec AG
Goeschwitzer Strasse 51-52 Jena Germany

WKN: 531370;ISIN: DE0005313704;Index:Prime All Share,TECH All Share,TecDAX;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;

Related Links: Carl Zeiss Meditec AG
Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.